Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuti (NQ: IRWD )

6.435 -0.045 (-0.69%)
Streaming Delayed Price Updated: 1:16 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ironwood Pharmaceuti

< Previous 1 2 3 Next >
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... 
Via Newsfile
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.